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ABSTRACT 
Purpose 
Genome wide association studies have identified common single nucleotide 
polymorphisms (SNPs) at 83 loci associated with colorectal cancer (CRC) risk in 
European populations. Since germline variation can also influence patient outcome, 
we studied the relationship between these SNPs and CRC survivorship.  
 
Experimental Design 
For the 83 risk loci, 10 lead SNPs were directly genotyped, 72 were imputed and 1 
was not genotyped nor imputed, in 1,948 unrelated patients with advanced CRC 
from the clinical trials COIN and COIN-B (oxaliplatin and fluoropyrimidine 
chemotherapy ± cetuximab). A Cox survival model was used for each variant, and 
variants classified by pathway, adjusting for known prognostic factors. We imposed a 
Bonferroni threshold of P=6.6x10-4 for multiple testing. We carried out meta-analyses 
of published risk SNPs associated with survival. 
 
Results 
Univariate analysis identified six SNPs associated with overall survival (OS) 
(P<0.05); however, only rs9939049 in CDH1 remained significant beyond the 
Bonferroni threshold (Hazard Ratio [HR] 1.44, 95% Confidence Intervals [CI] 1.21-
1.71, P=5.0x10-5). Fine mapping showed that rs12597188 was the most significant 
SNP at this locus and remained significant after adjustment for known prognostic 
factors beyond multiple testing thresholds (HR 1.23, 95% CI 1.13-1.34, P=1.9x10-6). 
rs12597188 was also associated with poor response to therapy (OR 0.61, 95% CI 
0.42–0.87, P=6.6x10-3). No combinations of SNPs within pathways were more 
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significantly associated with survival compared to single variants alone and no other 
risk SNPs were associated with survival in meta-analyses. 
 
Conclusions 
The CRC susceptibility SNP rs9939049 in CDH1 influences patient survival and 
warrants further evaluation as a prognostic biomarker. 
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INTRODUCTION 
Each year, over a million people are diagnosed with colorectal cancer (CRC) 
worldwide. Clinical stage, which combines depth of tumour invasion, nodal status 
and distant metastasis [1], is the only routinely used marker of survival. Other factors 
thought to influence prognosis include lifestyle [2,3], systemic inflammatory response 
to the tumour [4], the tumour immunologic microenvironment [5] and the patient’s 
germline and the tumour’s somatic genetic profile [6-9]. 
 
Around 6% of CRC is associated with Mendelian susceptibility caused by the 
inheritance of rare high-impact germline mutations [10] including those responsible 
for familial adenomatous polyposis (FAP) (MIM 175100) [11], hereditary non-
polyposis CRC (HNPCC; MIM 114500) [12] and MUTYH-associated polyposis (MAP; 
MIM 608456) [13]. Increasingly, it is being recognised that as well as influencing 
CRC risk, germline variation plays a role in patient outcome with HNPCC and MAP-
associated CRC typically being associated with better prognosis than those with 
sporadic CRC [14-16]. 
 
Genome wide association studies (GWAS) have been successful in identifying single 
nucleotide polymorphisms (SNPs) robustly associated with an individual’s risk of 
developing CRC. As well as influencing risk, studies have suggested that some of 
these alleles may affect patient survival [17-22]. However, most studies have not 
been performed in the context of a clinical trial but have been retrospective in design 
with the inherent biases from variation in patient management. 
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We have previously studied the relationship between SNP genotype and patient 
outcome for 14 of the GWAS risk-loci by analysing patient data from two clinical trials 
- COIN and COIN-B [23]. Since this study, an additional 69 loci have been identified 
which influence CRC risk in European populations [24]. To gain a comprehensive 
understanding of the role of genetic variation on patient outcome we assessed the 
prognostic effects of all known CRC-risk SNPs in 1,948 advanced disease patients 
by further utilising COIN and COIN-B trial data. 
 
MATERIALS AND METHODS 
Samples 
We prepared blood DNA samples from unrelated patients with metastatic or locally 
advanced colorectal adenocarcinoma from the MRC clinical trials COIN 
(NCT00182715) [25] and COIN-B (NCT00640081) [26]. All patients gave fully 
informed consent for bowel cancer research (approved by REC [04/MRE06/60]). 
COIN patients were randomised 1:1:1 to receive continuous oxaliplatin and 
fluoropyrimidine chemotherapy, continuous chemotherapy and cetuximab, or 
intermittent chemotherapy. COIN-B patients were randomised 1:1 to receive 
intermittent chemotherapy and cetuximab, or intermittent chemotherapy and 
continuous cetuximab. 
 
Genotyping 
As previously described [27], 2,244 cases from COIN and COIN-B were genotyped 
using Affymetrix Axiom Arrays according to the manufacturer's recommendations 
(Affymetrix, Santa Clara, CA 95051, USA). Individuals were excluded from analysis if 
they failed one or more of the following thresholds: overall successfully genotyped 
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SNPs <95% (n=122), discordant sex information (n=8), classed as out of bounds by 
Affymetrix (n=30), duplication or cryptic relatedness (n=4), and evidence of non-
white European ancestry by PCA-based analysis (n=130). After quality control, we 
had whole genome SNP genotyping and derived imputation data on 1,950 patients, 
2 of whom had no data on survival and were excluded (n=1,948). For the 83 CRC-
risk loci, 10 lead SNPs were directly genotyped, 72 were imputed and one 
(rs2732875) was on the X-chromosome which was not genotyped nor imputed. Six 
SNPs (rs77776598, rs2735940, rs6933790, rs704017, rs6055286 and rs1741640) 
had info scores <0.7 and were excluded. 
 
Statistical analysis 
We used a Cox survival model with overall survival (OS; time from trial 
randomisation to death) as the primary measure. Univariate analyses were 
performed using GenABEL in R. Multivariate analyses were carried out using 
survival in R. The coxph function was used with prognostic covariates in 
COIN/COIN-B: sex (male vs. female: HR 0.87, 95% CI 0.78-0.97, P=9.7x10-4), World 
Health Organization (WHO) performance status (HR 1.42, 95% CI 1.31-1.56, 
P<2.0x10-16), resection status of the primary tumour (unresected/unresectable vs. 
local recurrence: HR 1.29, 95% CI 1.01-1.63, P=0.04), white blood cell (WBC) count 
(HR 1.03, 95% CI 1.03-1.04, P<2.0x10-16), platelet count (HR 1.00, 95% CI 1.00-
1.00, P<2.0x10-16), number of metastatic sites (HR 1.21, 95% CI 1.14-1.28, 
P=2.5x10-10), site of distant metastasis (yes vs. no: liver: HR 1.23, 95% CI 1.09-1.39, 
P=8.8x10-4; peritoneum: HR 1.34, 95% CI 1.16-1.54, P=6.4x10-5; nodal: HR 1.15, 
95% CI 1.04-1.28, P=7.5x10-3; other metastases: HR 1.31, 95% CI 1.15-1.51, 
P=7.9x10-5), KRAS status (mutant vs. wild type: HR 1.46, 95% CI 1.29-1.66, 
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P=3.5x10-9), BRAF status (mutant vs. wild type HR 2.29, 95% CI 1.79-2.93, 
P=4.8x10-11) and NRAS status (mutant vs. wild type: HR 1.47, 95% CI 1.08-1.99, 
P=0.01), together with other factors in COIN/COIN-B (age at randomisation, 
cetuximab treatment, chemotherapy regimen, chemotherapy schedule, treatment 
arm and trial), none of which affected prognosis [25,28]. Response to treatment was 
defined as complete or partial response and non-response was defined as stable or 
progressive disease at 12 weeks, and analyses were performed with the oddsratio 
function from the fmsb package in R. We used Bonferroni correction to adjust for 
multiple testing with a significance threshold set at P=6.6x10-4 (0.05/76 SNPs after 
exclusion of SNPs with poor imputation). 
 
Meta-analyses 
We collected published data for 6 CRC-risk SNPs previously associated with 
survival, albeit at nominally significant levels (P<0.05) (rs4939827 [17,19], rs961253 
[18,22], rs6983267 [18,21], rs10795668 [17,20], rs4444235 [22] and rs4925386 
[17,22]). These SNPs had been analysed in different cohorts: Colorectal Neoplasia 
Repository and North Central Cancer Treatment Group (NCCTG) [29]; Study on 
Colorectal Cancer in Scotland (SOCCS) [30]; Seattle Colon Cancer Family Registry 
(CCFR) [31]; Health Professionals Follow-up Study (HPFS), Nurses’ Health Study 
(NHS), Physicians’ Health Study (PHS), VITamins and Lifestyle Study (VITAL), 
Women’s Health Initiative (WH1 and WH2) [17]; Nurses’ Health Study (NHS), Health 
Professionals Follow-up Study (HPFS) [19]; and National Study of Colorectal Cancer 
Genetics (NSCCG) [22]. Meta-analyses were performed in R using the meta 
package. The metagen function was used to perform all analyses under a fixed 
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effect model, or random effects model where there was significant heterogeneity. I2 
test and Cochran’s Q tests were used for assessment of heterogeneity. 
 
Bioinformatics 
Linkage disequilibrium (LD) between SNPs was examined using the --ld command in 
PLINK. Forty-nine SNPs were located within, or close to, genes 
(https://www.ncbi.nlm.nih.gov/snp). Thirteen SNPs were associated with expression 
quantitative trait loci (eQTL) (https://gtexportal.org/home/). Data from GeneCards 
(https://www.genecards.org) was used to assess whether ≥2 genes or eQTLs had 
roles in signalling pathways: 8 genes/eQTLs functioned in GPCR, 6 in TGF-Beta, 5 
in ERK, 3 in Wnt, 3 in BMP, 3 in Hedgehog, 3 in PI3K-Akt, 3 in E-cadherin and 2 in 
Notch signalling. Combinations of SNPs within the same pathway were analysed for 
survival outcome by the Log Likelihood Ratio test using the coxph and anova 
functions in R. 
 
RESULTS 
We analysed blood DNA samples and survival data from 1,948 unrelated patients 
with advanced CRC from the UK national trials COIN [25] and COIN-B [26] (Table 1). 
We found no evidence of heterogeneity in OS between patients when analysed by 
trial (COIN vs. COIN-B, P=0.33), trial arm (P=0.49), type of chemotherapy received 
(OxMdG/XELOX; P=0.46), or cetuximab use (P=0.24), so combined these groups for 
prognostic analyses. In total, 35% of patients were female with a mean age at 
randomisation of 63 years (range 18-87 years, Table 1). We had over 70% power 
under an additive model to detect a HR of 1.15 for survival for SNPs with minor allele 
frequencies (MAFs)>30% and a HR of 1.25 for SNPs with MAFs>10%. 
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For the 83 CRC-risk loci, 10 lead SNPs were directly genotyped, 72 were imputed 
and 1 was on the X-chromosome which was not genotyped nor imputed. Univariate 
analyses identified six SNPs (rs9831861 at 3p21.1, rs35470271 at 3p22.1, 
rs16892766 at 8q23.3, rs7894531 at 10p14, rs9939049 at 16q22.1 and rs1078643 at 
17p12) that were nominally associated with OS (P<0.05) (Table 2). Only rs9939049 
was significant beyond the Bonferroni corrected threshold (HR 1.44, 95% CI 1.21-
1.71, P=5.0x10-5). rs9939049 lies within CDH1 in LD with rs9929218 (r2=0.99, 
D’=0.99), which we have previously reported having a prognostic effect [23]. 
 
We consider whether other SNPs at 16q22.1 might be more significantly associated 
with survival and analysed all SNPs in LD with rs9939049 for which we had genetic 
data. rs12597188 (directly genotyped, r2=0.75, D’=0.99) was the most significantly 
associated SNP (recessive model: HR 1.48, 95% CI 1.28-1.72, P=1.9x10-7). We 
considered rs12597188 in multivariate analyses with known prognostic factors in 
COIN/COIN-B (sex, WHO performance status, resection status of the primary 
tumour, WBC and platelet count, number of metastatic sites, site of distant 
metastasis, and KRAS, BRAF and NRAS mutation status). rs12597188 remained 
significant beyond the Bonferroni corrected threshold (HR 1.23, 95% CI 1.13-1.34, 
P=1.9x10-6). Patients that were homozygous for the minor allele had a median 
decrease in life expectancy of 5 months compared to patients that were homozygous 
or heterozygous for the wild type allele. 
 
We sought whether rs12597188 was associated with response to oxaliplatin-
fluoropyrimidine chemotherapy after 12 weeks of treatment (likely to be correlated 
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with survival, n=1162 patients). Patients that were homozygous for the minor allele 
had significantly worse response (54/142 responded, 38.0%), as compared to 
patients that were heterozygous or homozygous wild-type (512/1020 responded, 
50.2%) (OR 0.61, 95% CI 0.42–0.87, P=6.6x10-3). This association was not seen in 
patients who also received cetuximab (51.0% versus 49.1%, n=786) with significant 
heterogeneity between these groups (I2=75.2%, Cochran’s Q test: P=0.04). 
 
We tested whether combinations of variants classified by pathway influenced 
survival. Eight SNPs lie within or near to genes that function in the GPCR signalling 
pathway, six in the TGF-Beta signalling pathway, five in the ERK signalling pathway, 
three in each of the Wnt, BMP, Hedgehog, PI3K-Akt and E-cadherin signalling 
pathways and two in the Notch signalling pathway (Table 3). No combinations of 
SNPs within specific pathways were more significantly associated with survival 
beyond the single most significant SNP in that pathway alone. 
 
Six CRC-risk SNPs (rs4939827, rs961253, rs6983267, rs10795668, rs4444235 and 
rs4925386) have previously been associated with survival [17-22], although none 
have been independently replicated [30,32,33]. We reviewed published survival data 
for these SNPs [17,19,22,29-31] and carried out meta-analysis with our data. No 
SNPs were associated with survival under fixed or random effects models (Figure). 
 
DISCUSSION 
Using an independent series of over 5,000 cases with CRC, we have previously 
validated rs9929218 in CDH1 as a prognostic biomarker [23]. We have extended 
these analyses herein and shown that rs12597188 is the most significantly 
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associated SNP at this locus. Our data suggests that patients homozygous for the 
minor allele of rs12597188, equating to ~12% of patients, have worse survival, with a 
median decrease in life expectancy of 5 months (in the advanced disease setting). 
Another study has provided further support for CDH1 variants having a genuine 
prognostic effect [20]. Our observations herein are limited to patients with stage 4 
disease. It is noteworthy that we have previously shown rs9929218 in CDH1 was not 
associated with survival amongst patients with Stage 1-3 (pre-metastatic) disease 
(HR=1.19, 95% CI 0.93-1.52, P=0.18) although there was no significant difference 
between the associations in patients with Stage 1-3 and Stage 4 disease (Pinteraction= 
0.48) [23]. Larger studies of pre-metastatic patients may help clarify the potential 
prognostic role of this biomarker in a population based setting. It is also important to 
note that the effect sizes for CDH1 variants are modest and will need to be combined 
with other germline and somatic prognostic factors to have any role in patient 
management; we are currently modelling potential combined effects in the advanced 
disease setting. 
 
rs12597188, rs9939049 and rs9929218 are in strong LD with rs16260 [34] in the 
CDH1 promoter which down-regulates CDH1 expression [35]. CDH1 encodes E-
cadherin. Patients homozygous for the minor alleles of these variants would be 
expected to have reduced E-cadherin expression. E-cadherin functions as a 
transmembrane glycoprotein involved in intercellular adhesion, cell polarity and 
tissue morphology and regeneration [36]. Critically, its loss represents a defining 
feature of the epithelial to mesenchymal transition during metastasis. CDH1 variants 
are therefore plausible prognostic biomarkers which influence this process. 
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Beyond CDH1 variants, the next CRC-risk loci most associated with survival was 
rs16892766 at 8q23.3. However, this variant was not significant after Bonferroni 
correction and was not significant in an independent cohort of >5000 patients with 
CRC [23]. Furthermore, our meta-analyses did not support a prognostic role for six 
other risk loci previously associated with survival. Given that our study was well 
powered to find variants with HRs>1.15, it is likely that no other low penetrance 
CRC-risk loci identified to-date have clinically-actionable effects on survival.  
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TABLES 
 
Table 1 – Clinicopathological data for patients in COIN and COIN-B 
 
 COIN  COIN-B 
No. cases with blood 
DNA 
2078  196 
    
No. with genotyping data 
after QC 
1778  170 
    
Total no. deaths 
(% of cases) 
1557 (75)  99 (51) 
    
Median follow-up (SD) 2.4 (2.2)  2.0 (4.4) 
    
% Female 34  42 
    
Age at randomisation, N 
(%) 
   
<65 years 
65–69 
70–74 
75–79 
≥80 years 
Missing 
Mean (SD) 
1203 (58) 
422 (20) 
318 (15) 
124 (6) 
9 (<1) 
2 (<1) 
62.0 (9.6) 
 
115 (59) 
35 (18) 
31 (16) 
10 (5) 
5 (3) 
0 (0) 
61.7 (10.4) 
    
Stage (%)    
1 
2-3 
4 
Unknown 
0 (0) 
0 (0) 
2078 (100) 
0 (0) 
 
0 (0) 
0 (0) 
196 (100) 
0 (0) 
    
Tumour site, N (%)    
Colona 
Rectumb 
Unknown 
1103 (53) 
951 (46) 
24 (1) 
 
124 (63) 
71 (36) 
1 (1) 
aColon defined as cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, 
descending colon and sigmoid colon. bRectum defined as rectosigmoid junction and rectum.
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Table 2: Univariate analysis of CRC-risk SNPs and overall survival 
  Additive Model Recessive Model 
Locus SNP Directly 
genotyped or 
imputed info 
score 
HR 95% CI P HR 95% CI P 
1p32.3 rs12143541 0.98 1.01  0.92-1.12 0.80 0.88 0.64-1.21 0.42 
1p34.3 rs61776719 0.81 1.01 0.92-1.11 0.77 0.98 0.83-1.15 0.78 
1p36.12 rs72647484 0.88 1.03 0.89-1.19 0.67 1.12 0.56-2.24 0.76 
1q25.3 rs4546885 0.92 0.98 0.91-1.07 0.69 0.90 0.77-1.06 0.20 
1q41 rs6658977 0.99 0.93 0.87-1.01 0.11 0.87 0.75-1.01 7.5x10-2 
2q11.2 rs11692435 0.85 1.01 0.85-1.19 0.92 2.48 1.23-4.97 0.01 
2q33.1 rs11893063 0.92 1.05 0.96-1.14 0.28 1.10 0.96-1.26 0.19 
2q33.1 rs7593422 0.98 1.01 0.94-1.09 0.77 1.00 0.88-1.14 0.99 
2q35 rs13020391 0.95 0.96 0.89-1.04 0.36 0.89 0.76-1.04 0.13 
3p21.1 rs9831861 1.00 0.94 0.87-1.01 0.11 0.86 0.75-1.00 4.6x10-2 
3p22.1 rs35470271 0.94 1.01 0.91-1.12 0.81 0.64 0.42-0.98 4.1x10-2 
3q13.2 rs12635946 0.97 0.98 0.91-1.06 0.60 0.97 0.83-1.13 0.71 
3q26.2 rs35446936 0.85 0.98 0.88-1.08 0.65 1.03 0.74-1.42 0.87 
4q24 rs17035289 DG 0.94 0.85-1.05 0.28 1.06 0.73-1.56 0.74 
4q31.21 rs75686861 0.97 1.05 0.93-1.19 0.40 0.92 0.70-1.19 0.52 
5p13.1 rs1445011 0.99 1.02 0.94-1.11 0.59 1.02 0.85-1.21 0.85 
5q31.1 rs639933 0.80 1.01 0.91-1.12 0.87 1.01 0.81-1.26 0.95 
6p12.1 rs62404966 0.97 1.05 0.96-1.14 0.30 1.21 0.98-1.48 7.2x10-2 
6p21.2 rs1321310 0.98 0.94 0.86-1.03 0.19 0.91 0.71-1.16 0.44 
6p21.31 rs16878812 0.99 1.04 0.93-1.17 0.49 1.30 0.86-1.96 0.22 
6p21.32 rs9271770 0.98 1.04 0.95-1.15 0.39 0.96 0.71-1.35 0.88 
6p21.33 rs3131043 DG 1.03 0.95-1.10 0.50 1.01 0.88-1.15 0.91 
6p24.1 rs2070699 DG 1.01 0.93-1.08 0.86 1.02 0.90-1.16 0.77 
6q21 rs6928864 0.97 0.90 0.79-1.03 0.13 0.72 0.37-1.38 0.32 
7p12.3 rs10951878 0.99 1.04 0.96-1.11 0.34 1.02 0.91-1.15 0.71 
7p12.3 rs3801081 1.00 1.05 0.97-1.14 0.19 1.02 0.86-1.22 0.78 
8q23.3 rs16892766 DG 1.23 1.08-1.39 1.3x10-3 1.83 0.95-3.53 7.1x10-2 
8q24.21 rs6983267 DG 1.06 0.99-1.15 0.11 1.10 0.97-1.26 0.13 
9p21.3 rs1412834 1.00 1.01 0.94-1.08 0.83 0.99 0.87-1.12 0.84 
10p14 rs7894531 1.00 0.88 0.81-0.96 2.6x10-3 0.77 0.63-0.93 8.4 x10-3 
10q24.2 rs2193352 1.00 1.01 0.93-1.10 0.81 0.97 0.76-1.24 0.82 
10q25.2 rs12255141 0.95 0.94 0.83-1.07 0.35 1.29 0.71-2.34 0.39 
11p15.4 rs4450168 0.76 1.09 0.94-1.26 0.24 1.21 0.63-2.34 0.56 
11q13.4 rs57796856 0.99 1.02 0.94-1.09 0.65 1.00 0.88-1.13 1.00 
11q13.4 rs4944940 0.86 1.01 0.81-1.26 0.93 0.66 0.16-2.64 0.56 
11q23.1 rs3087967 DG 1.05 0.98-1.14 0.18 1.12 0.94-1.32 0.21 
12p13.31 rs10849438 0.89 1.00 0.88-1.14 0.97 1.37 0.79-2.36 0.26 
12p13.32 rs12818766 0.96 0.96 0.87-1.06 0.43 1.08 0.79-1.46 0.64 
12p13.32 rs3217810 0.73 0.98 0.84-1.14 0.75 0.73 0.35-1.54 0.41 
12q13.13 rs11169572 0.99 1.05 0.97-1.13 0.24 1.12 0.98-1.28 0.10 
12q13.3 rs7398375 0.73 0.99 0.87-1.11 0.91 0.83 0.61-1.14 0.26 
12q24.12 rs597808 0.99 0.96 0.89-1.04 0.29 0.97 0.85-1.11 0.64 
12q24.21 rs7315438 0.97 1.04 0.96-1.13 0.30 1.09 0.95-1.26 0.21 
13q13.2 rs9537521 0.86 0.99 0.90-1.08 0.77 0.91 0.75-1.10 0.33 
13q13.3 rs12427600 0.97 1.02 0.94-1.11 0.68 0.92 0.74-1.15 0.46 
13q22.1 rs45597035 0.94 1.00 0.92-1.09 1.00 0.93 0.78-1.12 0.45 
13q22.3 rs1330889 0.96 1.02 0.91-1.14 0.78 0.89 0.58-1.36 0.59 
13q34 rs7993934 0.93 1.00 0.92-1.09 0.97 0.96 0.80-1.14 0.62 
14q22.2 rs35107139 0.86 1.00 0.91-1.09 0.93 0.96 0.89-1.05 0.42 
14q22.2 rs1570405 0.97 1.01 0.93-1.09 0.78 0.95 0.87-1.04 0.23 
15q13.3 rs16969681 0.99 1.03 0.91-1.15 0.65 1.04 0.66-1.65 0.85 
15q13.3 rs73376930 0.95 1.04 0.95-1.13 0.40 1.02 0.81-1.28 0.89 
15q13.3 rs16959063 0.97 0.93 0.80-1.25 0.61 0.93 0.69-1.25 0.61 
15q13.3 rs17816465 0.96 1.07 0.97-1.17 0.16 1.07 0.83-1.39 0.58 
15q22.31 rs4776316 0.74 1.00 0.88-1.13 0.94 1.03 0.72-1.47 0.88 
15q23 rs10152518 0.90 0.97 0.87-1.07 0.52 1.21 0.89-1.63 0.23 
15q26.1 rs7495132 0.97 1.00 0.89-1.11 0.95 0.91 0.63-1.33 0.63 
16q22.1 rs9939049 1.00 1.12 1.03-1.21 8.1x10-3 1.44 1.21-1.71 5.0x10-5 
16q23.2 rs61336918 0.99 0.96 0.88-1.04 0.31 0.87 0.72-1.05 0.14 
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16q24.1 rs2696839 0.93 1.00 0.92-1.08 0.98 1.00 0.87-1.14 0.97 
16q24.1 rs899244 0.96 1.02 0.93-1.12 0.68 0.92 0.70-1.20 0.53 
17p12 rs1078643 0.85 0.94 0.84-1.05 0.30 1.45 1.03-2.03 3.2x10-2 
17p13.3 rs73975588 0.97 1.05 0.93-1.19 0.43 0.96 0.54-1.69 0.88 
18q21.1 rs7226855 DG 0.99 0.92-1.07 0.83 0.95 0.83-1.10 0.50 
19p13.11 rs285245 0.98 0.95 0.79-1.14 0.57 NA NA NA 
19q13.11 rs73039434 0.76 1.09 0.84-1.43 0.51 NA NA NA 
19q13.2 rs9797885 0.91 1.00 0.92-1.09 0.94 1.05 0.95-1.16 0.35 
19q13.33 rs12979278 0.92 0.98 0.91-1.06 0.65 1.02 0.95-1.10 0.51 
20p12.3 rs961253 DG 0.99 0.92-1.07 0.84 0.97 0.84-1.13 0.71 
20p12.3 rs6085661 0.99 1.00 0.93-1.08 0.90 1.12 0.97-1.28 0.11 
20q13.12 rs2179593 0.98 0.96 0.88-1.05 0.37 0.89 0.72-1.11 0.31 
20q13.13 rs6066825 DG 0.97 0.90-1.05 0.46 1.01 0.86-1.18 0.93 
20q13.13 rs4811050 DG 1.01 0.92-1.11 0.86 1.00 0.77-1.31 0.98 
20q13.13 rs1810502 0.83 1.07 0.98-1.17 0.15 1.07 0.90-1.26 0.44 
20q13.13 rs6091213 0.91 1.03 0.94-1.12 0.54 1.01 0.82-1.25 0.92 
20q13.33 rs3787089 0.78 1.03 0.93-1.14 0.54 1.03 0.82-1.31 0.79 
HR: Hazard ratio, CI: Confidence interval, P: P-value, SNP: Single nucleotide polymorphism, 
NA: Not applicable. DG: Directly genotyped. Only rs9939049 at 16q22.1 (bold) was significant 
beyond the Bonferroni corrected threshold of P=6.6x10-4. 
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Table 3: Variants classified by signalling pathway 
Signalling pathway SNPs 
GPCR rs2070699, rs4776316, rs3801081, rs9537521, 
rs35107139, rs6066825, rs73039434, rs62404966 
TGF-Beta rs62404966, rs12427600, rs4776316, rs35107139, 
rs7226855, rs73376930 
ERK rs4546885, rs62404966, rs7993934, rs35107139, 
rs9939049 
Wnt rs75686861, rs12427600, rs73376930 
BMP rs12427600, rs4776316, rs73376930 
Hedgehog rs75686861, rs12427600, rs73376930 
PI3K-Akt rs4546885, rs16878812, rs597808 
E-cadherin rs17816465, rs16959063, rs9939049 
Notch rs12427600, rs73376930 
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LEGEND TO FIGURE 
Meta-analysis of six CRC risk-SNPs previously associated with survival. 
Forest plots shown using a fixed effect model. rs10795668 and rs4939827 
showed evidence of between-study heterogeneity (I2=72%, Cochran’s 
Q P=0.01 and I2=69%, Cochran’s Q P<0.01, respectively); however, neither 
were associated with survival when also considered under a random effects 
model (P=0.58 and P=0.22, respectively). Note - Results from Tenesa et al., 
2010 [30] and Morris et al., 2015 [22] were not adjusted for prognostic factors; 
Cicek et al., 2009 [29] adjusted for tumour characteristics at diagnosis, 
mismatch repair status, tumour site and stage; Passarelli et al., 2011 [31] 
adjusted for age at diagnosis and race; Phipps et al., 2012 [17] adjusted for 
age, and sex (VITamins and Lifestyle Study); Garcia-Albeniz et al., 2013 [19] 
adjusted for age, race, sex, tumour stage, grade of differentiation, aspirin use, 
smoking status, alcohol consumption, consumption of meat, and, calcium and 
folate intake. The survival measure used by Phipps et al., 2012 [17], Garcia-
Albeniz et al., 2013 [19], Tenesa et al., 2010 [30] and Passarelli et al., 2011 
[31] was diagnosis to death with any cause mortality, Cicek et al., 2009 [29] 
used overall survival or when censored at eight years, and Morris et al., 2015 
[22] used the date of recruitment to date of death or when censored at five 
years. Where appropriate, the inverse HR of those reported is shown to 
ensure the allele analysed for each study is consistent. HR: Hazard ratio. CI: 
Confidence Interval. 
